The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BRTX | -15.85% | -97.86% | -53.63% | -100% |
| S&P | +14.49% | +91.09% | +13.83% | +723% |
Biorestorative Therapies Inc. engages in developing therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders including obesity and diabetes. Its initial investigational therapeutic product being called BRTX-100 focuses on treating damage by autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process., The company was founded on June 13, 1997 and is headquartered in Melville, NY.
No news articles found for BioRestorative Therapies.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.01M | -94.9% |
| Gross Profit | -$0.05M | -130.8% |
| Gross Margin | -435.51% | -507.0% |
| Market Cap | $11.57M | -3.9% |
| Market Cap / Employee | $1.05M | 0.0% |
| Employees | 11 | 0.0% |
| Net Income | -$3.04M | -178.4% |
| EBITDA | -$3.66M | -63.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.60M | -59.6% |
| Accounts Receivable | $0.01M | -91.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -125.35% | -81.9% |
| Return On Invested Capital | -175.56% | -45.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.90M | -65.0% |
| Operating Free Cash Flow | -$2.90M | -70.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.99 | 1.45 | 2.04 | 2.39 | 98.43% |
| Price to Sales | 37.48 | 24.68 | 38.05 | 24.05 | -74.60% |
| Price to Tangible Book Value | 1.06 | 1.56 | 2.26 | 2.72 | 110.84% |
| Enterprise Value to EBITDA | -0.42 | 0.17 | -1.78 | -1.97 | 131.28% |
| Return on Equity | -96.9% | -117.2% | -137.1% | -207.7% | 284.08% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
